found the contract details.
Torii Pharmaceutical will pay up to $100 million for the Japanese licensing rights to Keryx's experimental therapy for high phosphorous levels in the blood
Up to $20 million of that money will become available by April, 2008. They have proven themselves to be ideal partners for smaller U.S.-based biotechnology companies seeking development and commercial partners in Japan," said Michael S. Weiss, chairman and CEO of Keryx, about his new partners.